NASDAQ •
Healthcare •
Biotechnology •
Quote as of 05/08/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization495.93 mln
Float307 mln
Earnings Date07/31/2026
Piotroski F-Score
2
/ 9
Weak
Beneish M-Score
-3.37
Reliable
1-Year Forecast
11.57
Transformational upside
Relative Strength
11
/ 100
Significantly lagging
Debt / Equity
-2.72
Negative equity
ROE
-849
Deeply negative
Business Description
Ocugen is a Pennsylvania-based medical company founded in 2013 that develops treatments for eye diseases and infectious illnesses. Its most advanced work focuses on gene therapies targeting inherited retinal conditions such as retinitis pigmentosa and macular degeneration, with several candidates currently in clinical trials. The company is also working on treatments for knee cartilage damage and a range of vaccines, including those for COVID-19 and seasonal flu, supported by partnerships with research institutions and international manufacturers.
